What question did this study set out to answer?

The aim is to investigate the role of anti-CD38 therapy in managing plasma cell-rich acute rejection in kidney transplant patients.

March 28, 2026Open Access

WCN26-4970 Plasma Cell-Rich Acute Rejection in a Young Kidney Transplant Patient and the Role of anti-CD38 Therapy

Key Points

The aim is to investigate the role of anti-CD38 therapy in managing plasma cell-rich acute rejection in kidney transplant patients.
Analysis of 57 solid organ transplant cases, focusing on acute rejection events.
Evaluation of multiple interventions including immunosuppressive therapy and intravenous immunoglobulin.
Assessment of graft-related outcomes and norovirus eradication.
67% of patients showed improvement in gastrointestinal symptoms.
Only 14% reported stable graft function or active rejection.
Evidence of norovirus eradication in stool was noted in 5% of cases.

Abstract

Table 1.(Continued) Study characteristics (n=57) Study characteristics Value Type of transplant, n (%) Kidney transplant alone 28 (49) Solid organ transplants including kidney, heart, lung, liver intestine and combined multiple transplants 36 (63) Solid organ transplants and others (haemopoietic stem cell transplants, immunosuppressed patients including haematological malignancies and solid tumours) 3 (5) Interventions*, n (%) Immunosuppressive therapy modification alone 14 (25) Nitazoxanide alone 6 (11) Intravenous immunoglobulin therapy alone 3 (5) Oral immunoglobulin therapy alone n 9 (16) Combination of treatments 17 (30) Faecal microbiota transplant 2 (4) Supportive management 4 (7) Others 5 (9) Reported outcomes, n (%) Improvement in GI symptoms 38 (67)Improvement of extra-GI symptoms 2 (4)Reporting of graft-related outcomes (stable function/rejection) 8 ( 14)Evidence of eradication of norovirus in stool 3 ( 5)No/minimal improvement in symptoms 13 ( 23)Reporting of adverse drug reactions 1 (2)* One study was conducted with multiple treatment arms.Figure 1 and 2 included as follows.Conclusion: A wide range of interventions has been used to manage norovirus infections in SOT recipients; however, the evidence is limited to observational studies, and the findings are uncertain.Highquality RCTs are needed to establish treatment efficacy and safety.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.

Bookmark

View Full Paper

Cite This Study

Mortari et al. (Wed,) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e0975 https://doi.org/https://doi.org/10.1016/j.ekir.2026.105488

Bookmark

View Full Paper